JNJ vs PFE: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
PFE |
| Current Price |
$230.69 |
$26.33 |
| Fair Value Estimate |
$255.61 |
$33.85 |
| Upside to Fair Value |
+10.8%
|
+28.6%
|
| Market Cap |
$555.9B |
$149.8B |
| Forward P/E |
26.8x
|
19.3x
|
| EV / EBITDA |
18.5x
|
12.9x
|
| Price / Sales |
5.8x
|
2.4x
|
| Price / FCF |
28.2x
|
16.5x
|
| Revenue Growth YoY |
+9.9%
|
-1.2%
|
| Gross Margin |
69.1%
|
70.3%
|
| Operating Margin |
26.9%
|
24.7%
|
| Return on Equity |
26.5%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.54%
|
6.06%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
JNJ |
PFE |
| Zone Low |
$191.71 |
$25.39 |
| Zone High |
$217.27 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|